LeukemiaNCT00186147
Bone Marrow Grafting for Leukemia and Lymphoma
An observational study of Leukemia and Lymphoma, run by Stanford University at 1 site in United States.
Trial summary
The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Leukemia, Lymphoma, Hematologic Diseases
- What is being tested?
- collection and storage of tissue samples for research
- Type of treatment
- Surgery or procedure
- How many people
- 9,999 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 1988to Dec 2069
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All hematopoietic cell transplant recipients and donors who agree to participate
Inclusion Criteria:- All hematopoietic cell transplant recipients and donors who agree to participate
Exclusion Criteria:- Subject does not agree to participate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Stanford University School of Medicine
Stanford, California, 94305
About this study
The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.
Read the detailed description
The purpose of this study is to acquire critical tissue and biological samples that can be evaluated to elucidate underlying mechanisms of disease control, transplant related complications and overall outcomes
- Conditions
- Leukemia, Lymphoma, Hematologic Diseases
- Being tested
- collection and storage of tissue samples for research
- Medical subject headings
- Leukemia, Lymphoma, Hematologic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
collection and storage of tissue samples for researchProcedure or surgery
Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
| Study group | Role | What they receive |
|---|---|---|
| Graft recipients and donors | Not described Receives: Procedure: collection and storage of tissue samples for research |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identify and characterize proteins and genes that may contribute to the development and progression of cancer.
Measured: blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2005 (estimated)
- Study startMar 1988
- Primary completionDec 2069 (estimated)
- Study completionDec 2069 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukemiaStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 9,999 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), National Institutes of Health (NIH)
- Responsible party
- Sponsor
- Investigators
- David Miklos, Principal investigator, Stanford UniversityRobert S Negrin, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00186147
- Sponsor's protocol ID
- IRB-08903
- Other IDs
- P01CA049605
- Status last verified
- Dec 2025
- First submitted
- 13 Sep 2005
- Last updated
- 18 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bone Marrow Grafting for Leukemia and Lymphoma
- ClinicalTrials.gov ID
- NCT00186147
- Acronym / sponsor ID
- IRB-08903
- Conditions
- Leukemia, Lymphoma, Hematologic Diseases
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 9,999 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), National Institutes of Health (NIH)
- Study start
- Mar 1988
- Primary completion
- Dec 2069 (estimated)
- Study completion
- Dec 2069 (estimated)
- First posted
- 16 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.
Detailed description
The purpose of this study is to acquire critical tissue and biological samples that can be evaluated to elucidate underlying mechanisms of disease control, transplant related complications and overall outcomes
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Graft recipients and donors | – | Procedure: collection and storage of tissue samples for research |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All hematopoietic cell transplant recipients and donors who agree to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| collection and storage of tissue samples for researchTissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research. | Procedure or surgery | Graft recipients and donors |
Primary outcome
Identify and characterize proteins and genes that may contribute to the development and progression of cancer.
Time frame: blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Leukemia
Enrolling by invitationPhase 2
Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia
Acute Leukemia, High Risk, Acute Leukemia Refractory
RecruitingObservational study
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
Graft-versus-leukemia, Graft vs Host Disease
RecruitingObservational study
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
RecruitingObservational study
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Multiple Myeloma, Lymphoma, Non-Hodgkin
RecruitingPhase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Miklos principal investigator
Stanford University
Robert S Negrin principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Leukemia and Lymphoma, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 18 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identify and characterize proteins and genes that may contribute to the development and progression of cancer. (time frame: blood sample is collected prior transplant, periodically during the first three months and then indefinately at follow up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2025.